ArticleDermatology practical & conceptual2026
Efficacy of Intralesional Platelet-Rich Plasma in Treatment of Fingernail Onychomycosis: A Randomized Controlled Trial.
Article in Dermatology practical & conceptual, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEmerging evidence suggests that platelet-rich plasma (PRP) has an antifungal role.
objectivesTo investigate the efficacy of intralesional PRP in the treatment of fingernail onychomycosis. PATIENTS AND
methodsPatients with fingernail onychomycosis were randomized to receive oral terbinafine 250 mg daily for three months, six sessions of intralesional PRP, or both (PRP + terbinafine). Primary outcome of the study was change in onychomycosis severity index (OSI) at the end of follow-up. Two blinded investigators (investigators A and B) assessed the outcomes. The assessment was carried out per affected nail rather than per affected patient.
resultsTwenty, 18, and 23 patients were included in the terbinafine, PRP, and terbinafine + PRP groups, respectively, with 40, 51, and 50 nails treated in each respective group. OSI was comparable among study groups according to investigator A (terbinafine: 4 [IQRs: 4, 9], PRP: 6 [IQRs: 2, 12], PRP + terbinafine: 5 [IQRs: 3, 8]; p>0.9) and investigator B (terbinafine: 4 [IQRs: 3, 10], PRP: 6 [IQRs: 4, 10], PRP + terbinafine: 6 [IQRs: 3, 12]; P>0.9). Similarly, mycological cure (terbinafine: 20%, PRP: 35%, PRP + terbinafine: 34%; P=0.23), clinical cure (terbinafine: 23%, PRP: 27%, PRP + terbinafine: 32%; P=0.61), and complete cure (terbinafine: 20%, PRP: 27%, PRP + terbinafine: 28%; P=0.64) were comparable.
conclusionsSix sessions of intralesional PRP were effective in treating fingernail onychomycosis, making it a potential viable alternative for patients who may not respond well to oral antifungal medications or who experience adverse effects from these drugs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.